Abstract
Resistance to thyroid hormone (RTH) is a rare disease characterized by non-suppressed TSH in spite of high free thyroid hormone levels. Up to date, in the literature, there are more than 600 RTH cases, but co-incidental hypophyseal adenoma was reported in only 1 case. In the literature, despite reported cases with thyrotropinoma accompanying RTH, we could not find a case with somatotropinoma accompanying RTH. Here, we report a 34-yr-old male patient, who was admitted to the hospital with complaints of dyspnea, chest pain, and palpitation in 2003. His α-subunit value was normal and the α-subunit/TSH molar ratio was <1. His response to TRH stimulation test was normal. His TSH level was suppressed in the T3 suppression test. Hypophyseal magnetic resonance imaging showed a 6-mm hypophyseal microadenoma. Levels of all anterior hypophyseal hormones, including GH and IGF-I, were normal. Oral glucose tolerance test (OGTT)-GH suppression test was normal. The patient was followed with the diagnosis of RTH and incidental hypophyseal adenoma. After 3 yr, because of high levels of IGF-I: 901 ng/ml (68–324), the OGTT-GH suppression test was reported and no suppression was detected. Thus, the patient was referred to surgery with the pre-diagnosis of RTH and acromegaly. Immunohistochemistry was showed as strong GH staining with low Ki 67 index while TSH and other anterior hypophyseal hormones stainings were negative. Post-operative thyroid hormones were still high.
Similar content being viewed by others
References
Olateju TO, Vanderpump MPJ. Thyroid hormone resistance. Ann Clin Biochem 2006, 43: 431–40.
Refetoff S. Resistance to thyroid hormone: an historical overview. Thyroid 1994, 4: 345–9
Safer JD, Colan SD, Fraser LM, Wondisford FE. A pituitary tumor in a patient with thyroid hormone resistance: a diagnostic dilemma. Thyroid 2001, 11: 281–91.
Molitch ME. Pituitary incidentaloma. Endocrinol Metab Clin North Am 1997, 26: 725–40.
Watanabe K, Kameya T, Yamauchi A, et al. Thyrotropin-producing microadenoma associated with pituitary resistance to thyroid hormone. J Clin Endocrinol Metab 1993, 76: 1025–30.
Kong AP, Lam CW, Chan AO, Yiu SF, Tiu SC. Resistance tyhroid hormone in a Chinese family with R429Q mutation in the thyroid hormone receptor beta gene. Hong Kong Med J 2005, 11: 125–9.
Refetoff S, DeWind LT, DeGroot LJ. Familial syndrome combining deaf-mutism, stippled epiphyses, goiter and abnormally high PBI: possible target organ refractoriness to thyroid hormone. J Clin Endocrinol Metab 1967, 27: 279–94.
Beck-Peccoz P, Roncoroni R, Mariotti S, et al. Sex hormone-binding globulin measurement in patients with inappropriate secretion of thyrotropin (IST): evidence againts selective pituitary thyroid hormone resistance in nonneoplastic IST. J Clin Endocrinol Metab 1990, 71: 19–25.
Beck-Peccoz P, Persani L Medical management of thyrotropin-secreting pituitary adenomas. Pituitary 2002, 5: 83–8.
Andersen M, Hagen C, Frystyk J, Schroeder HD, Hagen C. Development of acromegaly in patients with prolactinomas. Eur J Endocrinol 2003, 49: 17–22.
Sakharova AA, Dimaraki EV, Chandler WF, Barkan AL. Clinically silent somatotropinomas may be biochemically active. J Clin Endocrinol Metab 2005, 90: 2117–21
Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 2002, 87: 3537–42.
Ando S, Sarlis NJ, Oldfield EH, Yen PM. Somatic mutation of TRβ can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor. J Clin Endocrinol Metab 2001, 86: 5572–6.
Karl M, Lamberts SW, Koper JW, et al. Cushing’s disease preceded by generalized glucocorticoid resistance: clinical consequences of a novel, dominant negative glucocoticoid receptor mutation. Proc Assoc Am Physicians 1996, 108: 296–307.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Berker, D., Aydin, Y., Tutuncu, Y.A. et al. Somatotropin adenoma and resistance to thyroid hormone. J Endocrinol Invest 32, 284–286 (2009). https://doi.org/10.1007/BF03346468
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03346468